KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Equity Income (2019 - 2025)

Historic Equity Income for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $86.7 million.

  • Royalty Pharma's Equity Income rose 30678.9% to $86.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.1 million, marking a year-over-year decrease of 2644.82%. This contributed to the annual value of $29.1 million for FY2025, which is 2644.82% down from last year.
  • Latest data reveals that Royalty Pharma reported Equity Income of $86.7 million as of Q4 2025, which was up 30678.9% from $18.9 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Equity Income registered a high of $86.7 million during Q4 2025, and its lowest value of -$66.6 million during Q4 2021.
  • Over the past 5 years, Royalty Pharma's median Equity Income value was -$27000.0 (recorded in 2022), while the average stood at $3.8 million.
  • Per our database at Business Quant, Royalty Pharma's Equity Income plummeted by 24440.78% in 2021 and then skyrocketed by 107374.57% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Equity Income stood at -$66.6 million in 2021, then surged by 84.28% to -$10.5 million in 2022, then skyrocketed by 626.59% to $55.1 million in 2023, then crashed by 175.99% to -$41.9 million in 2024, then skyrocketed by 306.79% to $86.7 million in 2025.
  • Its Equity Income stands at $86.7 million for Q4 2025, versus $18.9 million for Q3 2025 and -$30.6 million for Q2 2025.